Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines

NCT01235949 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01235949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
November 12, 2010
Completion date
December 8, 2012
Enrollment
850 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

infections, streptococcal